Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling-Reference-Cited by-同舟云学术

Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

Published:2023-06 Issue: Volume:162 Page:114627
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Estupiñán Óscar,Rey Verónica,Tornín Juan,Murillo Dzohara,Gallego Borja,Huergo Carmen,Blanco-Lorenzo Verónica,Victoria González M.,Rodríguez Aida,Moris Francisco,González Jessica,Ayllón Verónica,Ramos-Mejía Verónica,Bigas Anna,Rodríguez René

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference53 articles.

1. Sarcoma treatment in the era of molecular medicine;Grunewald;EMBO Mol. Med.,2020

2. Epidemiology and risk factors of osteosarcoma;Sadykova;Cancer Investig.,2020

3. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up;Casali;Ann. Oncol.,2018

4. Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies;Abarrategi;Stem Cells Int.,2016

5. Cancer stem cells as a source of drug resistance in bone sarcomas;Menéndez;J. Clin. Med.,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mithramycin and its analogs: Molecular features and antitumor action;Pharmacology & Therapeutics;2024-08

2. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma;eBioMedicine;2024-04

3. Current challenges and practical aspects of molecular pathology for bone and soft tissue tumors;Virchows Archiv;2024-01-16

4. Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells;Free Radical Biology and Medicine;2023-11

5. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma;2023-09-12